| Microbiota in health and diseases K Hou, ZX Wu, XY Chen, JQ Wang, D Zhang, C Xiao, D Zhu, JB Koya, ... Signal transduction and targeted therapy 7 (1), 135, 2022 | 1704 | 2022 |
| Modulating ROS to overcome multidrug resistance in cancer Q Cui, JQ Wang, YG Assaraf, L Ren, P Gupta, L Wei, CR Ashby Jr, ... Drug Resistance Updates 41, 1-25, 2018 | 580 | 2018 |
| Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance JQ Wang, Y Yang, CY Cai, QX Teng, Q Cui, J Lin, YG Assaraf, ZS Chen Drug Resistance Updates 54, 100743, 2021 | 182 | 2021 |
| RNA methylation and cancer treatment B Yang, JQ Wang, Y Tan, R Yuan, ZS Chen, C Zou Pharmacological research 174, 105937, 2021 | 179 | 2021 |
| Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer XY Liu, JQ Wang, CR Ashby Jr, L Zeng, YF Fan, ZS Chen Drug discovery today 26 (5), 1284-1292, 2021 | 116 | 2021 |
| ATP‐binding cassette (ABC) transporters in cancer: A review of recent updates JQ Wang, ZX Wu, Y Yang, QX Teng, YD Li, ZN Lei, KA Jani, N Kaushal, ... Journal of Evidence‐Based Medicine 14 (3), 232-256, 2021 | 115 | 2021 |
| Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1-and ABCG2-overexpressing cancer cells N Ji, Y Yang, CY Cai, ZN Lei, JQ Wang, P Gupta, S Shukla, SV Ambudkar, ... Cancer letters 440, 82-93, 2019 | 106 | 2019 |
| Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers J Jin, Y Xie, JS Zhang, JQ Wang, SJ Dai, W He, SY Li, CR Ashby Jr, ... Drug Resistance Updates 67, 100929, 2023 | 81 | 2023 |
| Discovery of 5-cyano-6-phenylpyrimidin derivatives containing an acylurea moiety as orally bioavailable reversal agents against P-glycoprotein-mediated mutidrug resistance B Wang, LY Ma, JQ Wang, ZN Lei, P Gupta, YD Zhao, ZH Li, Y Liu, ... Journal of medicinal chemistry 61 (14), 5988-6001, 2018 | 68 | 2018 |
| Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells ZX Wu, QX Teng, CY Cai, JQ Wang, ZN Lei, Y Yang, YF Fan, JY Zhang, ... Biochemical pharmacology 166, 120-127, 2019 | 63 | 2019 |
| Tetrandrine interaction with ABCB1 reverses multidrug resistance in cancer cells through competition with anti-cancer drugs followed by downregulation of ABCB1 expression D Liao, W Zhang, P Gupta, ZN Lei, JQ Wang, CY Cai, AAD Vera, L Zhang, ... Molecules 24 (23), 4383, 2019 | 59 | 2019 |
| VS-4718 antagonizes multidrug resistance in ABCB1-and ABCG2-overexpressing cancer cells by inhibiting the efflux function of ABC transporters N Ji, Y Yang, CY Cai, ZN Lei, JQ Wang, P Gupta, QX Teng, ZS Chen, ... Frontiers in Pharmacology 9, 1236, 2018 | 58 | 2018 |
| Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells W Zhang, YF Fan, CY Cai, JQ Wang, QX Teng, ZN Lei, L Zeng, P Gupta, ... Frontiers in pharmacology 9, 1097, 2018 | 57 | 2018 |
| Ulixertinib (BVD-523) antagonizes ABCB1-and ABCG2-mediated chemotherapeutic drug resistance N Ji, Y Yang, ZN Lei, CY Cai, JQ Wang, P Gupta, X Xian, DH Yang, ... Biochemical Pharmacology 158, 274-285, 2018 | 53 | 2018 |
| Venetoclax, a BCL-2 inhibitor, enhances the efficacy of chemotherapeutic agents in wild-type ABCG2-overexpression-mediated MDR cancer cells JQ Wang, JY Li, QX Teng, ZN Lei, N Ji, Q Cui, L Zeng, Y Pan, DH Yang, ... Cancers 12 (2), 466, 2020 | 49 | 2020 |
| Paclitaxel resistance related to nuclear envelope structural sturdiness ER Smith, JQ Wang, DH Yang, XX Xu Drug Resistance Updates 65, 100881, 2022 | 48 | 2022 |
| Tivantinib, A c-met inhibitor in clinical trials, is susceptible to ABCG2-mediated drug resistance ZX Wu, Y Yang, QX Teng, JQ Wang, ZN Lei, JQ Wang, S Lusvarghi, ... Cancers 12 (1), 186, 2020 | 45 | 2020 |
| Erdafitinib antagonizes ABCB1-mediated multidrug resistance in cancer cells W Feng, M Zhang, ZX Wu, JQ Wang, XD Dong, Y Yang, QX Teng, ... Frontiers in oncology 10, 955, 2020 | 44 | 2020 |
| Features of cytokine storm identified by distinguishing clinical manifestations in COVID-19 WX Shen, RC Luo, JQ Wang, ZS Chen Frontiers in public health 9, 671788, 2021 | 43 | 2021 |
| Overexpression of ABCB1 transporter confers resistance to mTOR inhibitor WYE-354 in cancer cells J Wang, DH Yang, Y Yang, JQ Wang, CY Cai, ZN Lei, QX Teng, ZX Wu, ... International journal of molecular sciences 21 (4), 1387, 2020 | 41 | 2020 |
Zhe-Sheng ChenCollege of Pharmacy and Health Sciences, St. John's UniversityPatvirtintas el. paštas stjohns.edu